While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a ...

Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares ...

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved ...

A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way ...

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...